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Increased survival of vascularized organ allografts in the rat has been achieved by 
active host immunization with donor antigen, passive immunization with alloantise- 
rum, and a combination of both (1-5). The original concept, as suggested by Kaliss, 
that immunological enhancement is mediated by host humoral factors, is still widely 
held,  although  the  exact  mechanisms  involved  in  its  initiation  and  maintenance 
remain  unresolved  (6).  However, passive transfer of serum from enhanced animals 
rarely increases survival of test aliografts, despite detection of humoral blocking factors 
in some enhancement models (7). The contributions to allograft enhancement by the 
cellular-immune responses have not been rigorously assessed, although evidence for in 
vivo activity of cells capable of causing specific unresponsiveness has been found in 
other animal systems: for example, host responses against tumors may be influenced 
by cells or cellular products (8-10), which also act in delayed hypersensitivity (11-13) 
and graft-versus-host reactions  (14-16).  In studies of transplantation  tolerance, in- 
duced neonatally, suppressor cells have been demonstrated primarily to be recirculat- 
ing T  cells which show specificity in vivo to donor strain tissues (17,  18). 
We have shown previously that spleen cells and infiltrating leukocytes isolated from 
well-functioning  cardiac  allografts  in  enhanced  adult  rats  suppress  spontaneous 
blastogenesis of normal syngeneic cells in vitro (19). Additionally, preliminary obser- 
vations in vivo have suggested that lymphoid cells from enhanced animals bearing a 
well-functioning organ aUograft are able to transfer a state of specific unresponsiveness 
to unmodified recipients (20). The present studies demonstrate the precise activity of 
thymocytes in the early phase of immunological enhancement, confirm the specificity 
of this effect, and describe the necessity of an intact thymus for continued survival of 
the grafted organ in an enhanced host. Our observations suggest that the phenomenon 
of enhancement  of organ  atlografts  induced  by  particular  immunizing protocols, 
involves cellular as well as humoral mechanisms. 
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Materials  and  Methods 
Animals.  Inbred male rats weighing 150-200 g were used in all experiments (Microbiological 
Associates, Walkerville, Md.). Lewis rats (Lew, Ag-B  l, RT1 I) acted as organ recipients; (Lew 
×  BN)FI  hybrids were used as heart donors. Brown  Norway rats (BN, Ag-B  ~, RT1 ~) were 
employed as an antigen source for in vitro assays and for production of ailoantiserum in Lew 
rats. Wistar Furth (WF, Ag-B  4, RT1 Y) spleen cells were used as antigen, and (Lew  ×  BN)FI 
hybrids as organ donors for specificity experiments. 
Heart Grafting.  Heterotopic cardiac grafts were transplanted to recipient abdominal vessels 
by using standard microvascular techniques. Ventricular activity was assessed by daily palpa- 
tion  through  the  flank.  Organ  rejection  was  taken  as  complete  cessation  of myocardial 
contractions. 
Thymectomy.  Under ether anesthesia, a midline cervico-thoracic incision was made and the 
sternum  split  in  its  upper  one-third.  The  thymus  was  exposed,  gently  teased  away  from 
surrounding tissues, and removed intact. Parathymic lymph nodes were always excluded from 
thymic tissue. 
Cardiac Implants.  Through  a  midline incision both  kidneys were  exposed and  the  renal 
vasculature clamped, avoiding damage  to  the  ureters.  Small  areas of kidney capsule were 
excised and pieces (=0.5 g) of myocardium placed bilaterally in the defects. The clamps were 
then removed and hemostasis secured. 
Alloantiserum.  Hyperimmune  Lew  anti-BN  serum  was  produced  in  a  group  of 50  Lew 
recipients of single orthotopic  BN  skin  grafts,  followed  by  eight  biweekly intraperitoneal 
injections of 108 pooled BN spleen, thymus and lymph node, and bone marrow cells. 1 wk after 
the final injection, the animals were bled and the serum pooled and stored at --70°C. The 
antiserum was cytotoxic (50% lysis) against BN lymphocytes at  1:256 dilution. 
Hyperimmune Lew anti-WF serum was obtained by skin grafting 10 Lew rats with WF skin 
followed by six biweekly intraperitoneal injections of 107- l0  s pooled WF spleen, thymus, lymph 
node, and bone marrow cells. 2 wk after the final injection, the animals were bled, the serum 
pooled, and stored at -70°C. The antiserum was cytotoxie against WF lymphocytes at a  1:512 
dilution. 
Cell Suspensions.  Single-cell suspensions were prepared from spleen, lymph nodes, or thymus 
by disrupting the organs in RPMI-1640 medium (Associated Biomedic Systems, Inc., Buffalo, 
N.Y.), filtering though cotton wool, and washing twice. Mononuclear leukocytes were harvested 
from heparinized peripheral blood after dilution three times in saline, and layering on Ficoll- 
Hypaque (sp gr 1.090, Pharmaeia, Upsala, Sweden). Erythrocyte-free splenic leukocytes were 
obtained after brief treatment  with  hypotonie ammonium  chloride and  washing;  the  final 
preparation  contained  <  0.1%  erythrocytes  (21).  Pure  preparations  of erythrocytes  were 
obtained by layering heparinized whole blood over Ficoll-Hypaque and centrifuging at 500 g 
for  10  min.  The  erythrocyte pellet was washed  twice in  Eagle's minimal essential medium 
(Associated Biomedic Systems, Inc.). This preparation contained <0.5% leukocytes. All trans- 
ferred cells were injected intravenously into recipient animals. 
Harvesting of Cellular Infiltrates.  Cardiac  allografts were  transplanted  in  groups  of 8-10 
animals.  The  procedures  used  in  the  collection  of  infiltrating  cells  are  modifications of 
techniques previously described (22). At serial intervals after grafting, the hearts were removed 
and cleaned of surrounding tissue and clot. Each myocardium was then diced in 5 ml of tissue 
culture medium  (RPMI-1640)  containing 0.005  M  Hepes (N  1 hydroxyethylpiperazine N-2 
ethane sulfonic) acid buffer (Calbiochem-Behring Corp., American Hoechst Corp., San Diego, 
Calif.) and 4% (vol/vol) heat-inactivated fetal calf serum (FCS) (Associated Biomedic Systems) 
with 0.1  ml 0.2%  EDTA  (sodium ethylene diaminetetracetic acid, Sigma Chemical Co., St. 
Louis, Mo.). The tissue was then expressed through 60-gauge stainless steel mesh and filtered 
through cotton wool. The suspension of infiltrating cells was centrifuged twice at 200 g for 15 
min, washed, and incubated for 20 min at 25°C, then 20 min at 37°C in 10 ml buffered RPMI- 
1640 containing 0.4 mg/ml deoxyribonuclease (DNAse, Pentex Biochemical, Kankakee, Ill.). 
The cell suspension was then  washed, resuspended, and layered over Ficoll-Hypaque. After 
centrifugation at 350 g for 15 min, the cells were collected from the interface layer, washed in 
medium, and counted. 
Lymphocyte-Mediated Cytotoxicity (LMC)1.  LMC  was determined by a  modification of the 1044  HENDRY  ET AL. 
technique of Brunner et al.  (23),  as previously described  (22).  Infiltrating cells  from cardiac 
allografts,  and leukoeytes from peripheral  blood, lymph nodes, and spleen were used as the 
attacking cell populations; donor strain (BN) thymocytes labeled with SlCr acted as target cells 
(Na251Cr 04, New England Nuclear, Boston, Mass).  Attacking to killer cells were assayed in a 
ratio  of 100:1.  SlCr-labeled  Lew  thymocytes were  used  as  controls.  All  LMC  assays  were 
incubated in microtiter plates (3040 Micro Test II, Falcon Labware, Div. of Becton, Dickinson 
& Co., Oxnard, Calif.)  for 4 h at 37°C. The percentage of specific cell lysis was calculated: 
percent  -- experimental cpm-control cpm/freeze thaw cpm-control cpm. 
Complement-Dependent Cytotoxicity (CDC).  Serial twofold dilutions of sera (25/zl) were incu- 
bated with 51Cr-labeled  BN lymph node cells  (1  ×  104 in 25/~1) for 60 min. The cells were 
washed twice, 50/~1 of rabbit complement (l:10 dilution)  (Pel-Freeze Biologieals,  Inc., Rogers, 
Ark.)  was added to the target cells and serum and incubated at 22°C for 90 min. After this 
incubation  150/~1 of medium was added and the microtiter plates were centrifuged at 200 g. 
The supernates were then counted for released SlCr. 
Surface-Bound Immunoglobulin (SIg + ) Lymphoid Cells.  Lymphocyte suspensions were incubated 
with fluorescein isothiocyanate conjugated rabbit anti-rat IgG (heavy and light chain) (N. L. 
Cappel Laboratories, Inc., Cochranville, Pa.). Cells  with surface immunoglobulin were easily 
detected by fluorescence microscopy (24). By using this technique, thymocyte suspensions used 
for transfer were found to contain <1% SIg+ cells. 
Identification of T Lymphocytes.  Rabbit anti-rat brain antiserum was produced and rendered 
specific for T  lymphocytes by the method  of Golub  (25).  The  heat-inactivated  serum  was 
absorbed with (Lew ×  BN)F1 erythroeytes and lyophilized liver powder six times, ultracentri- 
fuged and diluted  1  : 10 before indirect immunofluoreseence cell staining. Antiserum (25 tal) was 
mixed with  106 rat lymphoid cells in 50/LI medium and incubated for 30 min at 4°C. After 
washing the cells thrice in medium, the suspension was centrifuged for 10 min at 200 g. FITC 
conjugted goat anti-rabbit IgG (50/~1) (N. L. Cappel Laboratories, Inc.) was then mixed with 
the pellet,  incubated  for 30 min at 4°C and washed thrice with Hanks' medium containing 
0.1% sodium azide. The cell suspension was then examined for immunofluorescence membrane 
cell staining. 
Identification of Mononuclear Cells Bearing an Fc Receptor.  A 2% solution of ox erythrocytes was 
incubated  with  a  subagglutinating  diluion  of rabbit  anti-bovine erythrocyte antibody (IgG 
fraction) (Baltimore Biological, Baltimore, Md.) for 90 min at 37°C (26).  10/~1 lymphocytes (5 
×  10n/ml)  was added to 10/~1 of the IgG-coated bovine erythrocytes (2%) and  10/~1 FCS in a 
microtiter tray, and centrifuged for 15 min at 250 g at 4°C. After incubation at 4°C for 45 rain, 
the percent  of rosette-forming lymphocytes was determined by counting the cells  under the 
fluorescence microscope with acridine orange stained cover slips. 
T~ypsmization of Transferred Thymocytes.  Thymocytes were incubated in protein-free medium 
containing 10/~l/ml of trypsin (Sigma Chemical Co.) for 30 min at 37°C. The cells were then 
washed  three  times  with  culture  medium  before  transfer  into  syngeneic  recipients  of test 
allografts. Under these gentle conditions the majority of SIg is removed from spleen cells  (E. 
Milford, unpublished observations). 
Statistics.  Statistical significance was determined by use of Student's two-tailed t test. 
Results 
Previous experiments in this laboratory have established the optimal immunization 
regimen for enhancement  of Lew recipients of (Lew  X  BN)F1 cardiac allografts (5). 
Best graft survival occurs when Lew animals are pretreated with 5  l07 BN spleen cells 
and  1 ml of Lew anti-BN alloantiserum  11  and  10 d  before transplantation,  respec- 
tively. This pretreatment  regimen increases graft survival to a minimum of 26 d, with 
20% of the grafts functioning indefinitely, significant prolongation when compared to 
grafts in untreated  hosts  (mean survival time  ±  SD [MST]  =  7  ±  1 d, P  <  0.001). 
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observations that  thymocytes from enhanced, engrafted animals  prolong test  graft 
survival after adoptive transfer into unmodified hosts (20). 
Graft  Survival  after  Cell  Transfer.  Transfer of l0  s  syngeneic thymocytes from  en- 
hanced Lew rats bearing well functioning (Lew ×  BN)F1 cardiac grafts (thymocyte 
donors), to unmodified animals receiving (Lew  ×  BN)F1  cardiac grafts 24 h  later 
(test graft recipients), successfully prolonged the test grafts (MST  =  4  :t=  3 d, P  < 
0.001,  Fig.  1).  However, transfer of l0  s thymocytes from normal  Lew rats or from 
unmodified Lew rats 6  d  after receiving (Lew  ×  BN)F1  cardiac allografts did not 
effect test graft survival (MST  --  6  ±  1 d). 
The  kinetics  of the  phenomenon  of transferred  unresponsiveness  mounted  by 
thymocytes from enhanced engrafted rats was then examined. Thymocytes harvested 
3  or  12  d  after transplantation  did  not  prolong test  graft  survival  after adoptive 
transfer  (MST  =  7  :t=  1 d),  whereas  cells  transferred  a  9  d  produced  moderate 
prolongation of test graft survival (MST =  9  ±  2 d, P <  0.05). 
Having established that transfer of thymocytes 6 d after transplantation gave best 
results, the effect of cell dose was then investigated (Fig. 2). The longest survival of 
test grafts was obtained upon transfer of l0  s thymocytes (MST =  14 =1= 3 d). Correct 
cell dosage was crucial, as transfer of fewer or greater numbers of cells was ineffectual 
(MST of test grafts after transfer 100 thymocytes --  8  +  2 d,  10  7 thymocytes =-  7.5 
±  1 d, 5  X  l0  s cells--  8  ±  1 d). 
Effect  of the  Enhancing  Protocol.  The  role  of each  component  of the  enhancing 
protocol on the generation of thymic suppressor activity was studied.  Either active 
(spleen cell) or passive (antiserum) enhancement alone, 11 and 10 d before transplan- 
tation, increased graft survival to 9.5 ±  1 and 10 -  2 d, respectively (27). Thymocytes 
harvested 6 d after cardiac transplantation from these actively or passively pretreated 
animals and transferred into test graft recipients did not confer prolonged test graft 
survival  (7.5  +  1.5 d  and 6.5  +  1 d, respectively). Thus, the entire immunization 
regimen for the engrafted thymocyte donor, with  both antigen  and  antibody, was 
necessary for optimal test graft survival. 
The type of antigenic stimulus used for active enhancement was then assessed (Fig. 
3).  Potential recipients were immunized with 5  ×  10 7 BN spleen cells, erythrocyte- 
free splenic leukocytes, or leukocyte-free erythrocytes, 11 d before heart transplanta- 
tion. In all cases this was followed 1 d later by 1 ml ofalloantiserum. 6 d after grafting, 
10  s thymocytes were transferred adoptively to syngeneic rats who received a  (Lew 
×  BN)F1 test heart graft 24 h later. Best survival of test grafts occurred when whole 
spleen  cells,  containing  both  leukocyte  and  erythrocyte fractions  were  used.  No 
significant prolongation was observed when leukocytes alone were used  (MST  =  7 
±  1 d);  intermediate increase in survival of test grafts was noted with erythrocytes 
alone (MST  ffi  10  ±  2 d, P <  0.001). 
To determine the influence of the antigenic stimulus provided by the vascularized 
heart graft itself on the production ofthymocytes with suppressor activity, thymocytes 
were obtained from enhanced rats who had received either no cardiac allograft or 
who were given various substitute antigenic stimuli on the day of grafting (Fig. 4). 
Thymocytes from enhanced Lew animals who had received BN spleen cells and Lew 
anti-BN serum  but  no  heart  grafts,  did  not  prolong survival  (MST  -~  7  ±  1 d). 
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Ftc.  1.  Survival curves are noted for test (Lew  X  BN)F1 cardiac allografts placed in unmodified 
recipients 24 h after adoptive transfer of 10  a thymocytes from syngeneic enhanced engrafted animals. 
The sources of thymocytes are:  (O)  normal Lew;  (0)  unmodified Lew  bearing acutely rejecting 
(Lew  X  BN)FI cardiac allografts at 6 d; and enhanced Lew rats bearing well functioning (Lew 
X  BN')FI  cardiac allografts at 3 d  (A), 6 d  (&), 9 d  (El), and 12 d  (11). There are 8-16 animals in 
each group. Thymocytes transferred at 6 d prolong test graft survival significantly (P <  0.001). 
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Fro.  2.  The effect of dose of transferred thymocytes from enhanced recipients on test graft survival 
is shown. Cells were adoptively transferred in doses of 106 (0),  t0  r (11), l0  s (A), and 5  X  l0  s (O). 
There are 8-12 animals in each group. Transfer of 10  s cells produced optimal results (P <  0.001). 
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Fno.  3.  The effect of the initial active immunizing stimulus of the enhanced recipient upon survival 
of test  allografts  after  adoptive  transfer  of  10  8  thymocytes  is  noted.  Groups  of 8-12  enhanced 
thymocyte recipients were pretreated with 5  X  10  7 BN whole spleen cells  (&), 5  X  10  7 leukocyte 
free BN erythrocytes  (O),  or  5  X  10  7  erythrocyte free  BN splenic leukocytes  (I),  11  d  before 
transplantation, followed  by  1 ml of hyperimmune serum  1 d  later. Although pretreatment with 
erythrocytes alone increases the effect of transferred thymocytes, optimal activity is achieved by 
pretreatment with whole spleen cells (P <  0.001). 
instead  of  the  heart  graft,  did  not  prolong  test  graft  survival  after  transfer  of 
thymocytes.  However, when  myocardial  tissue was implanted  into the kidney cortices 
of enhanced  animals,  transfer of thymocytes  to  syngeneic  hosts 6  d  later resulted  in 
significant  prolongation  of  test  grafts  (MST  =  10  +  2  d,  P  <  0.001).  These SPECIFIC  UNRESPONSIVENESS  BY  THYMOCYTE  TRANSFER  1047 
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Fie.  4.  The effect of the allografi in enhanced recipients upon transferred thymocytes mediating 
survival of test allografts is shown. Groups of 9-14 Lew animals were immunized actively with 5 
X  107 BN spleen cells 11  d  before and  1 ml Lew anti-BN antiserum  10 d  before receiving (In)  5 
x  106 (Lew  X  BN)FI  spleen cells, (V)  a  (Lew  X  BN)F1  myocardial implant under the kidney 
capsule, (&) a  vascularized (Lew  X  BN)FI cardiac allografl, or (O)  no further antigenic stimulus. 
Both myocardial implants and a  vascularized graft produced prolongation of test graft survival (P 
< 0.001). 
experiments show the necessity for active and passive immunization of the enhanced 
graft  recipient  and  suggest  the  need  for a  second  antigenic stimulus of sufficient 
magnitude to marshall a sustained host response against it. 
Transfer of Viable or Nonviable  Thymocytes and Serum.  The possibility was tested that 
passive transfer of cytophilic antibodies or antigen-antibody complexes on the surfaces 
of transferred thymocytes from enhanced thymocyte donors might themselves increase 
graft survival (Table I). The ability of viable thymoeytes which had been trysinized, 
or thymocytes which were allowed to shed overnight at 37°C in tissue culture medium, 
was undiminished in prolonging test graft survival. Conversely, transfer of 108 heat 
killed thymoeytes (56°C for 30 min), failed to produce graft prolongation (MST  = 
7.5+  ld). 
The effect of passive transfer of serum from ehnanced recipients of well functioning 
grafts on survival of test grafts was assessed.  Enhanced engrafted animals were bled 
at 6 d after transplantation and their serum pooled and stored at -70°C. This serum 
was then injected into unmodified Lew recipients of (Lew  ×  BN)F1 cardiac grafts, 
by using the regimen of French and Batchelor (Table I)  (3). The serum transfer had 
no effect on test graft survival (MST  =  7.5  ±  1 d). 
Specificity  of the  Suppressor Effect.  The  specificity of the suppressor  effect against 
donor strain and third party strain grafts was examinated by using the RT1 disparate 
WF strain (Fig.  5). Lewis animals were pretreated with 5  X  10  7 WF spleen cells and 
1 ml of Lew anti-WF alloantiserum 11 and 10 d before transplantation, respectively. 
With this enhancement regimen (Lew  ×  WF)F1 cardiac grafts survived 21  ±  5 d; 
such grafts placed in unmodified animals survived 7 ±  1 d  (P <  0.001).  The survival 
of  (Lew  ×  WF)F1  allografts,  after  transfer  of thymocytes  from  enhanced  Lew 
recipients of (Lew  ×  WF)F1  heart grafts was prolonged to  10  ±  2 d  (P <  0.002). 
However, when thymocytes from enhanced Lew recipients of (Lew  ×  BN)F1  heart 
grafts were transferred into unmodified Lew recipients of (Lew X  WF)F1 test grafts, 
no prolongation was noted (MST  ---  6  +  1 d). Similarly, (Lew X  BN)F1 heart grafts 
in Lew hosts survived only 6 zlz  1 d after syngeneic thymocyte transfer from enhanced 
animals bearing (Lew X WF)F 1 cardiac grafts. Hence, specificity of unresponsiveness 
to the original RT1 haplotype was demonstrated. 
Effect of Host Thymectomy on Enhancement.  Having demonstrated prolongation of test 
graft survival after thymocyte transfer, the effect of thymectomy on graft survival in 1048  HENDRY  ET AL 
TABtE  I 
Type of transfer*  No. animals  MST graft survival 
days 
Viable thymocytes (10  s) 
Trypsinized  5  14 ±  3:~ 
Cultured overnight  5  15 +  2:]: 
Heat-killed thymocytes (10  s)  8  7.5 •  1 
Serum  8  7.5 ±  I 
* Cells and serum were taken  from enhanced  Lew recipients of (Lew X  BN)F1 
cardiac grafts 6 d after transplantation. Cells were then transferred into unmodified 
Lew test graft recipients transplanted with a (Lew ×  BN)F1 heart 24 h later. The 
serum was transferred: 1 ml intravenously at time of transplant,  1 ml intraperito- 
nealty at 24 h, and 0.5 ml intraperitoneally at 48, 72, and 96 h, respectively (3). 
$ (P< o.ool). 
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FiG.  5.  Prolongation of test cardiac allografts after transfer of thymocytes from enhanced animals 
is  a  strain  specific phenomenon.  The  survival of appropriate  cardiac  allografts  is  prolonged 
significantly (P < 0.001) in Lew recipients immunized with specific antigen and antiserum. There 
is no prolongation of  specific  test grafts after thymocyte transfer from enhanced recipients immunized 
with inappropriate  (third party) antigen and antibody, before grafting. 
enhanced rats was examined  (Fig.  6).  Groups of animals  underwent  thymectomy at 
various intervals. Thymectomy at 6 wk followed by enhancement and engraftment 8- 
10 wk later  had  no effect  upon  graft  survival  (MST  =  32  -  4  d)  as compared to 
nonthymectomized enhanced  recipients.  Similarly,  thymectomy immediately before 
grafting, or at 3 d  after transplantation  of enhanced recipients did not diminsh graft 
function  (MST  =  31  ±  3  d  and  31  ±  4  d, respectively).  However, thymectomy 6 
and  10 d after transplantation  reduced significantly graft survival to 16:1=  3 d and  14 
±  2 d, respectively (=10 and 4 d  after thymectomy, P <  0.001). Thus, removal of the 
thymus  at  a  critical  period  after  transplantation  severely  diminished  the  effect  of 
enhancement on prolonged graft survival. 
Surface Properties of Infiltrating  Cells.  Infiltrating cells  harvested  at  6  d  from well- 
functioning heart  grafts and cells from spleens of test  graft recipients were identified 
by their  surface  characteristics  (Table  II). These  cells  were  then  compared  to cells 
isolated at 6 d  from spleens and from acutely rejecting grafts in unmodified animals. 
Infiltrating cells recovered from cardiac allografts were incubated at  22°C overnight 
to permit shedding of cytophilic antibodies, resuspended and washed (28, 29). Spleen 
weights 6 d  after transplant  and overall numbers of cells in spleens were comparable SPECIFIC  UNRESPONSIVENESS  BY THYMOCYTE  TRANSFER  1049 
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Fro.  6.  The effect of thymectomy on  survival of cardiac allografts in enhanced  hosts is shown. 
Thymectomy  of the  enhanced  recipients 6-10  d  after transplantation  causes  acute  rejection  of 
cardiac allografts.  Thymectomy at other intervals has no effect upon  long-term survival.  Day of 
thymectomy: A, none; ~7, -56; O, 0; O, 3; ", 6; 1"3, 10. 
TABLE  II 
Lymphocyte Subpopulations* in Test Graft Recipients Comparison with Acute Rejection~ 
Fc +  Re-  T  cells  B cells  ceptor cells 
LMC 
6d  12d 
%  %  %  % 
Cardiac allografts 
Test grafts  40:1:9  34:1:  9  30:1:2  0  0 
Acute rejection  70:1:6  35  :t:  13  22:1:4  37:1:3  -- 
Recipient spleens 
Test-grafted animals  36 :t:  4  61  :t:  11  47:1:2  0  0 
Acutely rejecting animals  65:1:6  37  :lz  7  26 :t:  5  14:1:3  -- 
* Mean  ±  standard deviation. 
~: Each of four experiments include cell pools from grafts of 8-10 animals. 
in both groups of animals. The numbers of T  lymphocytes in both hearts and spleens 
of test graft recipients were diminished as compared to animals acutely rejecting their 
grafts. Conversely, there were increased numbers of SIg +  and Fc +  cells in the spleens 
of rats from the experimental  group, as compared to unmodified recipients. 
Lymphocyte-Mediated Cytotoxidty.  Infiltrating cells from well-functioning heart grafts 
and leukocytes  from peripheral  blood, lymph nodes (cervical,  axillary,  and brachial) 
and spleens  of 34 test  graft  recipients  were  tested  for direct  LMC  in  four separate 
experiments, 6 and 12 d after transplantation.  Allospecific killing was never observed. 
This finding contrasts to significant  LMC  (37%  -4-  3) mounted by cells isolated from 
acutely rejecting cardiac  allografts at 6  d, and by the spleen cells of the unmodified 
hosts (14%  :1:  2)  at 6  d, peaking at 8  d  after transplantation  (40%  :!:  3, P  <  0.001). 
Complement-Dependent Cytotoxicity.  Sera from untreated  recipients  of acutely  reject- 
ing grafts, from enhanced rats bearing well-functioning grafts, and from animals with 
test  grafts  surviving  for prolonged  periods  after  thymocyte  transfer,  were  collected 
serially after transplantation  and tested for complement-dependent  cytotoxicity  (Fig. 
7). Unmodified  Lew recipients  of (Lew  ×  BN)F1  cardiac  allografts showed  a rising 
titer of antibody around the time of acute rejection at 5-7 d, which persisted for 1 wk 
thereafter.  Little  CDC  activity  was  demonstrable  in  enhanced  recipients  of well- 
functioning  grafts.  Test  graft  recipients  which  had  received  syngeneic  thymocytes 1050  HENDRY  ET  AL. 
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Fio.  7.  Serial determinations of CDC is noted. There is an increase in cytoto×icity during the time 
of acute rejection in unmodified recipients of heart grafts, and marked increase in activity around 
the time of rejection in animals who had received immunologically unresponsive thymocytes from 
enhanced, engrafted animals. 0, untreated; A, enhanced; I, suppressed. 
from enhanced engrafted thymocyte donors showed  no  cytotoxicity for  7 d  after 
transplantation. However, cytotoxicity became intense (~90% lysis) by day 12, near 
the time of rejection, and still remained high at day 20. Additionally, CDC was tested 
against nylon wool separated T  and B lymphocyte enriched BN lymph node cells. 
CDC  against separated lymph node cells by using serum at  day  12  and  14  from 
acutely rejecting and suppressed animals revealed comparable killing ofT and B cells. 
Discussion 
Just as graft rejection appears to be the culmination of many different interrelated 
cellular and antibody-mediated responses,  the induction and maintenance of graft 
survival in immunologically enhanced animals appears increasingly to be related to 
a  series of connected host events.  Although immunological enhancement was  first 
described as a humoral phenomenon, passive transfer of  serum from enhanced animals 
rarely  increases  survival  of test  allografts.  We  have  shown  previously  that  cell 
populations  producing  immunological unresponsiveness  emerge  in  enhanced,  en- 
grafted animals  (19, 20). Transferred thymocytes and spleen  cells from enhanced 
recipients  of cardiac  allografts increase  significantly the  survival of test  grafts  in 
unmodified syngeneic animals. The phenomenon seems to be mediated primarily by 
T  cells, as thymocytes produce optimal prolongation of test  grafts, although nylon 
wool nonadherent spleen  cells have somewhat greater activity than the nylon wool 
adherent  fraction. The concept  that  cell-mediated suppression  of the immune re- 
sponses acts as an active immunoregulatory mechanism has been demonstrated in 
many systems, including depression of antibody formation (30, 31), delayed hypersen- 
sitivity responses  (11-13),  the mixed lymphocyte reaction (32, 33), graft-versus-host 
responses  (14-16) and immunological tolerance. Indeed, Mitchison in  1960 demon- 
strated evidence for active suppressor  mechanisms which continuously maintain a 
tolerant state (34). 
In  the  present  experiments, the  role  of thymocytes in  enhancement of cardiac 
allografts has been defined further and the immunological specificity of the phenom- 
enon established. Adoptive transfer of thymocytes from enhanced thymocyte donors 
to unmodified syngeneic test graft recipients doubled the survival of donor strain test 
allografts.  This  activity  was  highly  time  dependent,  detected  only  6-9  d  after 
transplantation,  and  also  markedly  dose  dependent.  That  5  X  10  s  transferred 
thymocytes gave  significantly poorer  results  than  108  thymocytes suggests  a  fine SPECIFIC UNRESPONSIVENESS BY THYMOCYTE TRANSFER  1051 
balance existing between suppressor and some other cell types whose effects become 
evident above or below the optimal dose of cells with suppressor activity Such dose 
dependency has been described in other models (35). Additionally, acute rejection of 
previously well-functioning allografts in enhanced animals occurs after thymectomy 
between  days  6  and  10  only,  the  same  time  as  the  optimal  effect of transferred 
thymocytes. This confirms the importance of an intact thymus at a  critical period 
after induction of enhancement. The influence of the thymus has also been noted in 
studies  of tolerance,  in  which  thymectomy may  prevent  induction  of neonatal 
tolerance to skin grafts (36). 
Prolonged allograft survival after passive cell transfer in adults has been described 
predominantly in immunocompromised hosts. Specific tolerance to skin grafts in the 
rat  has been  achieved by transferring T-enriched  thoracic  duct lymphocytes from 
neonatally tolerized rats to sublethally irradiated syngeneic recipients (18). Transfer 
of normal  thymocytes to slightly irradiated  young, syngeneic chickens also effects 
responsiveness towards allografts, as survival of subsequent skin grafts is prolonged 
(37).  Kilshaw and Brent  have induced unresponsiveness to skin allografts in adult 
mice by pretreatment with donor strain crude liver extract combined with Bordetella 
pertussis vaccine and anti-lymphocyte serum (35). This state of unresponsiveness can 
be  adoptively transferred to partially immunosuppressed recipients by splenocytes 
harvested from mice with long surviving grafts. Additionally, Stuart et al. have noted 
that transfer of splenocytes from combined active and passive enhanced recipients of 
kidney allografts,  harvested  80-150  d  after  transplantation  delayed  the  onset  of 
rejection of test grafts in five of six instances (38). Batchelor et al., however, failed to 
demonstrate  such  an  effect  in  renal  allografted  rats  that  were  passively  but  not 
actively enhanced (39). 
We have shown that thymocytes from engrafted rats enhanced by combined active 
and passive means prolong the survival of test allografts when transferred to untreated 
syngeneic hosts.  In these studies, the full protocol used to initiate enhancement in 
engrafted thymocyte donors was critical  for optimal production  of cells mounting 
specific unresponsiveness. Test graft survival was not prolonged when leukocytes alone 
were used as the active enhancing agent; erythrocytes alone increased graft function 
moderately. In previous studies on immunizing regimens using the present  model, 
Baldwin et al. showed that optimal enhancement occurs only when a combination of 
erythrocytes and  leukocytes and  serum  are  used  (27).  Possibly,  erythrocytes and 
leukocytes  work  through  different  mechanisms,  i.e.,  erythrocytes  predominantly 
through cellular host responses and leukocytes predominantly through humoral host 
responses.  Thus,  to  demonstrate suppressor  cell  activity in  rats  bearing enhanced 
organ allografts, the grafted animals must be both actively and passively immunized. 
Our results may also offer an explanation for the partial success of Stuart et al and 
the inability of Batchelor et al. to prolong test graft survival after adoptive transfer of 
lymphoid ceils (38,  39).  The production of immunological unresponsiveness in this 
model was also dependent upon a  further antigenic stimulus after combined active 
and passive immunization (Fig. 4). Optimal test graft survival after cell transfer was 
obtained with a  vascularized cardiac allograft. A small piece of myocardium placed 
beneath the kidney capsules gave moderate test graft prolongation, although no effect 
occurred when allogeneic splenocytes were used as the stimulus. Prolonged exposure 
to allogeneic tissue or a requirement for organ-specific immunization after active and 1052  HENDRY ET AL. 
passive enhancement may be an absolute requirement for the development of sup- 
pressor activity. 
The antigenic specificity of transferrable unresponsiveness using BN and WF donor 
strain  animals was  striking  (Fig.  5).  These  strains  were  chosen  because  they  are 
incompatible for all known major histocompatibility antigens, including genes with 
the RT1-A class  I  antigens  (containing/~2 microglobulin), and  the RT1-B  region 
which includes genes for MLR, Ia, and Ir. 
Because the cells with the best suppressor activity were derived from the thymus, 
the effect would appear to be attributed primarily to viable T lymphocytes. As trypsin 
or shedding overnight in medium did not effect the activity of these cells, transfer of 
antigen or antigen-antibody complexes is unlikely. Additionally, the inability of serum 
from enhanced, engrafted animals to prolong test graft survival after passive transfer, 
would  suggest  that  soluble  factors  or  actively  produced  alloantibody  alone  are 
insufficient to inhibit allograft rejection. 
Because  passive  transfer  of thymocytes from  enhanced  animals  is  not  as  fully 
effective in prolonging graft survival as the complete active and passive enhancement 
protocol itself, additional host factors may come into play to maintain the integrity 
of the enhanced state. Cellular and humoral host responses by test graft recipients 
after transfer of thymocytes from enhanced, engrafted donors are different from those 
previously demonstrated either in studies of ummodified animals acutely rejecting 
their  grafts  or  in  enhanced  rats  bearing  well  functioning grafts  (5,  19,  22).  The 
reduction in numbers of T  lymphocytes both in grafted hearts and in spleens of test 
graft recipients is paralleled by the complete absence of direct LMC mounted by the 
isolated cells.  Despite the failure of these animals to produce cell-mediated cytotox- 
icity, cytotoxic antibody is markedly increased around and subsequent to the time of 
graft rejection. Thus, the data suggest a preferential effect of suppressor like activity 
upon cytotoxic T-cell function, with a lesser effect upon antibody-producing cells. In 
contrast, passive enhancement of recipients of both heart or kidney allografts in the 
same (Lew ×  BN)F1 ~  Lew rat strain combination produces only minor alterations 
in generation of cytotoxic T  lymphocytes, but  ablates  the generation of cytotoxic 
antibody (5, 40). Histologically, this lack of antibody production in passively enhanced 
recipients  of kidney  grafts  is  manifest  by  abolition  of IgG-mediated  necrotizing 
vasculitis  and  glomerulitis.  Furthermore,  the  combination  of active  and  passive 
enhancement  of recipients  of cardiac  allografts,  does  not  dampen  the  extent  of 
infiltration of cytotoxic T  lymphocytes into the allografted hearts, a situation quite 
distinct from that noted in test graft recipients in the present experiments (19). Thus 
different biological  manipulations  can  modify separate  pathways  in  the  complex 
cellular and  humoral  host  responses  towards  alloantigens in  the  organ  allografts. 
These mechanisms must be  assessed  independently for fuller understanding of the 
total immunological behavior against such tissues. 
Summary 
Prolonged survival of vascularized organ allografts has been produced in unmodi- 
fied  inbred  rats  by  transfer  of thymocytes  from  enhanced,  engrafted,  syngeneic 
animals. For these thymocytes to increase significantly the survival of test allografts 
they must be harvested 6-9 d  after transplantation. Thymectomy of the enhanced, 
engrafted animals during the same critical period causes acute rejection of otherwise SPECIFIC UNRESPONSIVENESS BY THYMOCYTE TRANSFER  1053 
long surviving grafts.  For optimal  effect, the  enhanced  thymocyte donor must  be 
actively and passively immunized and receive a  cardiac allograft. The necessity for 
erythrocytes in  the initial  active immunization regimen is noted. Additionally, the 
antigenic specificity of the suppressor effect has been established with two histoincom- 
patible donor rat strains. 
Cellular and humoral host responses mounted by test graft recipients after thymo- 
cyte transfer from enhanced, engrafted donors are different from those mounted either 
by unmodified animals acutely rejecting their grafts or by enhanced rats bearing well- 
functioning grafts. Numbers of T  lymphocytes are reduced in the grafted hearts and 
in the spleens of test graft recipients, a finding paralleled by the complete absence of 
specific  direct  lymphocyte-mediated cytotoxicity.  In  contrast,  cytotoxic  antibody 
production, although delayed, is increased in magnitude, peaking around the time of 
graft rejection. These studies provide evidence that different biological manipulations 
can modify separate pathways in the complex cellular and humoral responses towards 
organ  allografts. They demonstrate that  cellular immunity is critically involved in 
immunological enhancement of vascularized organ allografts, a phenomenon hitherto 
considered primarily humoral.  It seems clear that cells with suppressor activity are 
present within the thymus during the early phases of immunological enhancement. 
Received  for publication 16January  1979. 
References 
1.  Stuart,  F.  P.,  T.  Saitah,  and  F.  W.  Fitch.  1968. Rejection of renal allografts:  specific 
immunological suppression. Science (Wash. D.C.).  160:1463. 
2.  Ockner, S. A., R. D. Guttman, and R. R. Lindquist.  1970. Modification of rejection by 
active immunisation with bone marrow cells. Transplantation (Baltimore). 9:30. 
3.  French, M. E., andJ. R. Batchelor.  1969. Immunological enhancement of rat kidney grafts. 
Lancet. II:1103. 
4.  Stuart, F. P., D. M. Scollard, T. J. McKearn, and F. W. Fitch. 1976. Cellular and humoral 
immunity after allogeneic  renal transplantation in the rat. Appearance of anti-idiotypic 
antibody and its relationship to cellular immunity after treatment with donor spleen cells 
and alloantibody. Transplantation (Baltimore). 22:455. 
5.  Tilney, N. L., J. Bancewicz, W. Rowinski, J. Notis-McConarty, A. Finnegan, and D. Booth. 
1978. Enhancement of cardiac allografts in rats. Comparison of host responses to different 
treatment protocols.  Transplantation (Baltimore). 25:1. 
6.  Kaliss, N.  1958. Immunological enhancement of tumor homografts in mice. Cancer Res. 18: 
992. 
7.  Carpenter, C. B., A. J. F. D'Apice, and A. K. Abbas.  1976. The role of antibodies in the 
rejection and enhancement of organ allografts. Adv. Immunol. 22:1. 
8.  Greene, MI., S. Fujimoto, and A. H. Sehon. 1978. The characterization ofthymic suppressor 
factors regulating the immune response to tumor antigens.  XV. Protides of the biological 
fluids. Proc. XXV Colloquium.  H. Peeters, editor. Pergamon Press, Inc.  Elmsford,  N.Y. 
667. 
9.  Mitchell,  M.  S., and M.  B. Mokyr.  1972. Specific inhibition of receptors  for cytophilic 
antibody on macrophages by isoantibody.  Cancer Res. 32:832. 
10.  Fujimoto, S., M. I. Greene, and A. H. Sehon.  1976. Regulation of the immune response to 
tumor antigens.  II.  The nature  of immunosuppressor cells  in  tumor bearing hosts. J. 
Immunol. 116:800. 
11.  Asherson, G. L., M. Zombak, and R. M. Branes.  1971. The mechanism  of immunological 1054  HENDRY  ET  AL. 
unresponsiveness to picryl chloride and the possible role of antibody mediated depression. 
Clin. Exp. Immunol. 9:109. 
12.  Asherson, G. L., and M. Zembala. 1974. Suppression of contact sensitivity by T cells in the 
mouse. I. Demonstration that suppressor cells act on the effector state of contact sensitivity 
and their induction following in vitro exposure to antigen. Proc. R. Soc. Lond. Set. B.  187:329. 
13.  Phanusphak,  P., J.  W.  Moorhead,  and  H.  N.  Claman.  1974. Tolerance  and  contact 
sensitivity to DNFB in mice III. Transfer of tolerance with "suppressor T cells".  J. Immunol. 
113:1230. 
14.  Elkins, W. L.  1972. Cellular control of lymphocytes initiating graft versus host reactions. 
Cell. Immunol. 4:191. 
15.  Hardin, J. A., T. M. Chused, and A. D. Steinberg. 1973. Suppressor cells in the graft versus 
host reaction. J. Immunol. 3:650. 
16.  Pickel, K., and M. K. Hofman.  1977. Suppressor T cells arising in mice undergoing a graft 
versus host response. J. Immunol. 118:653. 
17.  Terman, D. S., P. Mirdon, and A. J. Crowle. 1971. Adoptive transfer of neonatal tolerance 
into normal mice. Fed. Proc. $0:.650. 
18.  Dorsch,  S.,  and  B.  Roser.  1977. Recirculating,  suppressor  T  cells  in  transplantation 
tolerance.J. Exp.  Med.  145:1144. 
19.  Tilney, N.  L., T. B.  Strom, D. B.  Booth, A. Finnegan, P. Lundin, and C. B. Carpenter. 
1977. Identification, cytotoxicity and suppressor activity of infiltrating cells from enhanced 
organ allografts. Transplant. Proc. 9:713. 
20.  Tilney, N. L., M. J. Graves, and T. B. Strom. 1978. Prolongation of organ allograft survival 
by syngeneic lymphoid cells.J. Immunol. 121:1480. 
21.  Boyle,  W.  1968. An  extension  of the  51Cr-release  assay  for  the  estimation  of mouse 
cytotoxins. Transplantation (Baltimore). 6:761. 
22.  Tilney, N. L., T. B. Strom, S. S. Macpherson, and C. B. Carpenter. 1975. Surface properties 
and functional characterization of infiltrating cells harvested from acutely rejecting cardiac 
allografts in inbred rats. Transplantation (Baltimore). 20:323. 
23.  Brunner, D. T., J. Manel, J. C. Cerottini, and B. Chapins.  1968. Quantitative assay of the 
lytic action  of immune  lymphoid cells on  5tCr-labeled allogeneic target  cells in  vitro: 
inhibition by isoantibody and by drugs. Immunology. 14:181. 
24.  Raft, M. L., M. Sternberg, and R. B. Taylor. 1970. Immunolgobulin determinants on the 
surface of mouse lymphoid cells. Nature (Lond.). 225:553. 
25.  Golub, E. S. 1972. The distribution of brain-associated 0 antigen cross reactive with mouse 
in the brain of other species. J. Immunol. 109:168. 
26.  Soullilou, J. P., C. B. Carpenter, A. J. F. D'Apice, and T. B. Strom.  1976. The role of non- 
classical, Fc receptor-associated Ag-B antigen  (Ia)  in rat  allograft enhancement. J.  Exp. 
Med.  143:405. 
27.  Baldwin, W. M., III, W. L. Null, J. Notis-McConarty, and N. L. Tilney. 1978. Enhanced 
allograft survival by combined active and passive immunization. Transplantation (Baltimore). 
25:121. 
28.  Tilney, N.  L., T.  B.  Strom,  S. G.  Macpherson,  and  C.  B.  Carpenter.  1976. Studies on 
infiltrating host  cells harvested from  acutely rejecting rat  cardiac allografts. Surgery (St. 
Louis). 79:209. 
29.  Strom, T.  B.,  N.  L. Tilney, J.  M.  Paradysz, J.  Bancewicz, and  C.  B.  Carpenter.  1977. 
Cellular components of allograft rejection: identity, specificity and cytotoxic function of 
cells infiltrating acutely rejecting allografts.  J. Immunol. 118:2020. 
30.  Baker, P. S., P. W. Stashak, D. F. Amsbaugh, B. Prescott, and R. F. Barth.  1970. Evidence 
for the existence of two functionally distinct types of cells which regulate the antibody 
response to type III pneumococcal polysaccharide.  J. Immunol. 105:1581. 
31.  Tada, T., M. Taniguchi, and K. Okumura.  1971. Regulation of homocytotropic antibody 
formation in the rat. III. Effect of thymectomy and splenectomy.J. Immunol. 106:1019. SPECIFIC UNRESPONSIVENESS  BY THYMOCYTE TRANSFER  1055 
32.  Rich,  S.  S.,  and  R.  R.  Rich.  1974. Regulatory mechanisms  in  cell  mediated  immune 
responses.  I. Regulation of MLT by alloantigen activated thymus derived iymphocytes. J. 
Exp.  Med.  140:1588. 
33.  Hirano,  T.,  and  A.  A.  Nordin.  1976. Cell  mediated  immuno  response  in  vitro.  I.  The 
development of suppressor cells and cytotoxic lymphocytes in mixed lymphocyte cultures. 
J. ImmunoL  116:1115. 
34.  Mitchison, N. A. 1969. Cell populations involved in the immune response. In Immunological 
Tolerance. M. Landy and W. Brown, editors. Academic Press, Inc., New York. 149. 
35.  Kilshaw, P. J., and L. Brent. 1977. Further studies on suppressor T cells in mice unresponsive 
to H-2 incompatible skin grafts.  Transplant.  Proc. 9:.717. 
36.  Gershon, R. K., and K. Kondo.  1970. Cell interaction  in the induction of tolerance: the 
role of thymic lymphocytes.J. Immunol.  18:723. 
37.  Droege, W. 1975. Immunosuppressive effect ofsyngeneic thymus cells in allografl rejection. 
Proc. Natl.  Acad.  Sci.  U. S. A.  72:2371. 
38.  Stuart, F. P., T. J. McKearn, and F. W. Fitch. 1976. Immunological enhancement of renal 
allografts by anti-receptor antibody. Surge~  (St.  Louis). 80:130. 
39.  Batchelor, J. R., L. Brent, and P. S. Kilshaw.  1977. Absence of suppressor cells from rats 
bearing passively enhanced kidney allografts. Nature (Lond.).  270:522. 
40.  Strom, T.  B.,  C.  B.  Carpenter,  M.  R.  Garovoy, A.  K.  Abbas, J.  M.  Corson, and J.  P. 
Soulillou.  1975. Modifications of the rat  alloimmune response by enhancing antibodies 
and the role of blocking factors in the survival of renal grafts. Transplantation  (Baltimore). 20: 
368. 